Pacific Biosciences of California (PACB) ended the recent trading session at $1.66, demonstrating a -1.19% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.72%. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.12%.
Shares of the maker of genetic analysis technology have appreciated by 15.86% over the course of the past month, outperforming the Medical sector's gain of 12.48%, and the S&P 500's loss of 0.9%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $42.1 million, indicating a 5.86% increase compared to the same quarter of the previous year.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.41 per share and revenue of $165.8 million. These results would represent year-over-year changes of +22.64% and +3.62%, respectively.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pacific Biosciences of California is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 159, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).